Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
75.63
+0.46 (0.61%)
Apr 13, 2026, 12:06 PM EDT - Market open
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts that cover Ionis Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $90.14, which forecasts a 19.19% increase in the stock price over the next year. The lowest target is $46 and the highest is $120.
Price Target: $90.14 (+19.19%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 8 | 9 | 9 | 9 | 10 | 10 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 22 | 22 | 23 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $100 → $111 | Strong Buy | Maintains | $100 → $111 | +46.77% | Apr 9, 2026 |
| Barclays | Barclays | Buy Maintains $95 → $106 | Buy | Maintains | $95 → $106 | +40.16% | Mar 26, 2026 |
| Needham | Needham | Strong Buy Maintains $103 → $105 | Strong Buy | Maintains | $103 → $105 | +38.83% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $110 → $120 | Strong Buy | Maintains | $110 → $120 | +58.67% | Mar 25, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $102 → $104 | Buy | Maintains | $102 → $104 | +37.51% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
840.27M
from 943.71M
Decreased by -10.96%
Revenue Next Year
1.49B
from 840.27M
Increased by 76.97%
EPS This Year
-4.19
from -2.38
EPS Next Year
-1.36
from -4.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 955.6M | 2.2B | |||
| Avg | 840.3M | 1.5B | |||
| Low | 749.1M | 970.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.3% | 156.9% | |||
| Avg | -11.0% | 77.0% | |||
| Low | -20.6% | 15.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.23 | 1.22 | |||
| Avg | -4.19 | -1.36 | |||
| Low | -4.60 | -3.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.